NASDAQ:AFMD

Affimed (AFMD) Stock Forecast, Price & News

$0.46

-0.01 (-2.11%)

(As of 09/26/2023 ET)

Compare

Today's Range: $0.45
▼
$0.49
50-Day Range: $0.46
▼
$0.63
52-Week Range: $0.45
▼
$2.55

Volume: 403,034 shs
Average Volume: 958,926 shs
Market Capitalization: $69.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Affimed MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 1,086.4% Upside
$5.50 Price Target
Short Interest: Healthy
1.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.95
Upright™ Environmental Score
News Sentiment: 0.27
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.85) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

418th out of 964 stocks

Biotechnology Industry

13th out of 26 stocks

3.4

Analyst's Opinion

Consensus Rating
Affimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Affimed has a forecasted upside of 1,086.4% from its current price of $0.46.
Amount of Analyst Coverage
Affimed has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.48% of the outstanding shares of Affimed have been sold short.
Short Interest Ratio / Days to Cover
Affimed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Affimed has recently decreased by 1.34%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Affimed does not currently pay a dividend.
Dividend Growth
Affimed does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Affimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.
Environmental Sustainability
The Environmental Impact score for Affimed is -1.95.

2.4

News and Social Media Coverage

News Sentiment
Affimed has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Affimed this week, compared to 1 article on an average week.
Search Interest
Only 11 people have searched for AFMD on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
4 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Affimed insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.80% of the stock of Affimed is held by insiders.
Percentage Held by Institutions
Only 30.82% of the stock of Affimed is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Affimed are expected to grow in the coming year, from ($0.85) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Affimed is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Affimed is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Affimed has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Affimed (NASDAQ:AFMD) Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Price History

30 days | 90 days | 365 days | Advanced Chart

AFMD Stock News Headlines

September 27, 2023 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Coverage Initiated by Analysts at StockNews.com

September 26, 2023 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Given "Overweight" Rating at Cantor Fitzgerald

September 27, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 25, 2023 | benzinga.com

What 6 Analyst Ratings Have To Say About Affimed

September 24, 2023 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23, 2023 | americanbankingnews.com

Affimed (NASDAQ:AFMD) Share Price Crosses Below 200-Day Moving Average of $0.69

September 21, 2023 | finance.yahoo.com

Affimed to Present at the Cantor Global Healthcare Conference 2023

September 12, 2023 | markets.businessinsider.com

Affimed Says FDA Grants Fast Track Designation For AFM13 With AlloNK To Treat R/r Hodgkin Lymphoma

September 27, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 7, 2023 | msn.com

Cantor Fitzgerald Reiterates Affimed N.V. (AFMD) Overweight Recommendation

September 7, 2023 | markets.businessinsider.com

Expert Ratings for Affimed

August 23, 2023 | finance.yahoo.com

Is Affimed NV Set to Underperform? Analyzing the Factors Limiting Growth

August 22, 2023 | finance.yahoo.com

Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

August 16, 2023 | barrons.com

Affimed N.V.

August 11, 2023 | markets.businessinsider.com

Where Affimed Stands With Analysts

August 11, 2023 | markets.businessinsider.com

Affimed (AFMD) Gets a Buy from H.C. Wainwright

August 11, 2023 | msn.com

Truist Securities Maintains Affimed N.V. (AFMD) Buy Recommendation

August 11, 2023 | finanznachrichten.de

Affimed N.V.: Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

August 9, 2023 | seekingalpha.com

Affimed Q2 2023 Earnings Preview

August 9, 2023 | finance.yahoo.com

Some Analysts Just Cut Their Affimed N.V. (NASDAQ:AFMD) Estimates

August 3, 2023 | finance.yahoo.com

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

August 1, 2023 | benzinga.com

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech's SNK01 NK Cells

July 31, 2023 | finance.yahoo.com

Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells

June 22, 2023 | finanznachrichten.de

Affimed N.V.: Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

June 22, 2023 | finance.yahoo.com

Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

June 9, 2023 | finance.yahoo.com

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

June 6, 2023 | finance.yahoo.com

Affimed (NASDAQ:AFMD) shareholders have endured a 78% loss from investing in the stock three years ago

See More Headlines

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings: 8/10/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AFMD
CUSIP: N/A
CIK: 1608390
Web: www.affimed.com
Phone: 496221674360
Fax: 49-6221-653-0777
Employees: 219
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.50
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +1,086.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-90,610,000.00
Net Margins: -357.49%
Pretax Margin: -359.20%
Return on Equity: -79.96%
Return on Assets: -60.31%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 5.05
Quick Ratio: 5.03

Sales & Book Value

Annual Sales: $43.58 million
Price / Sales: 1.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.31 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 149,340,000
Free Float: 143,664,000
Market Cap: $69.23 million
Optionable: Optionable
Beta: 2.11

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Adi Hoess M.D. (Age 62)
Ph.D., CEO, MD & Member of Management Board
Comp: $815.34k

Mr. Angus W. Smith (Age 41)
CFO & Member of Management Board
Comp: $671.27k

Dr. Wolfgang Fischer (Age 59)
MD, COO & Member of Management Board
Comp: $636.05k

Ms. Denise Mueller (Age 53)
Chief Bus. Officer & Member of Management Board
Comp: $618.98k

Dr. Andreas Harstrick M.D. (Age 62)
Chief Medical Officer & Member of Management Board
Comp: $527.2k

Dr. Arndt Justus Georg Schottelius M.D. (Age 57)
Ph.D., Chief Scientific Officer & Member of Management Board
Comp: $639.25k

Prof. Melvyn Little
Founder & Consultant

Mr. Michael Wolf (Age 56)
Head of Fin. & Admin.

Mr. Alexander Fudukidis
Head of Investor Relations & Director of Investor Relations

Mary Beth Sandin
VP of Marketing & Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.
What is Affimed's stock price forecast for 2023?: 8 Wall Street research analysts have issued 12 month price objectives for Affimed's shares. Their AFMD share price forecasts range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,086.4% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.
How have AFMD shares performed in 2023?: Affimed's stock was trading at $1.24 at the start of the year. Since then, AFMD shares have decreased by 62.6% and is now trading at $0.4636.
View the best growth stocks for 2023 here.
When is Affimed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our AFMD earnings forecast.
How were Affimed's earnings last quarter?: Affimed (NASDAQ:AFMD) released its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting analysts' consensus estimates of ($0.22). The biopharmaceutical company earned $1.51 million during the quarter, compared to analyst estimates of $4.83 million. Affimed had a negative trailing twelve-month return on equity of 79.96% and a negative net margin of 357.49%.
What other stocks do shareholders of Affimed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

What is Affimed's stock symbol?: Affimed trades on the NASDAQ under the ticker symbol "AFMD."
Who are Affimed's major shareholders?: Affimed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.82%), Renaissance Technologies LLC (0.39%), State Street Corp (0.38%), BNP Paribas Arbitrage SNC (0.35%), Intellectus Partners LLC (0.28%) and Goldman Sachs Group Inc. (0.21%).
How do I buy shares of Affimed?: Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Affimed's stock price today?: One share of AFMD stock can currently be purchased for approximately $0.46.
How much money does Affimed make?: Affimed (NASDAQ:AFMD) has a market capitalization of $69.23 million and generates $43.58 million in revenue each year. The biopharmaceutical company earns $-90,610,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.
How many employees does Affimed have?: The company employs 219 workers across the globe.
How can I contact Affimed?: Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial